The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67

This publication has 38 references indexed in Scilit:

• Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma
  Laboratory Investigation, 2013
• How Reliable Is Ki-67 Immunohistochemistry in Grade 2 Breast Carcinomas? A QA Study of the Swiss Working Group of Breast- and Gynecopathologists
  PLOS ONE, 2012
• Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
  JNCI: Journal of the National Cancer Institute, 2011
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
  Annals of Oncology, 2011
• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
  Journal of Clinical Oncology, 2010
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
  JNCI: Journal of the National Cancer Institute, 2009
• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
  Journal of Clinical Oncology, 2007
• Prognostic value of proliferation in invasive breast cancer: a review: Table 1
  Journal of Clinical Pathology, 2004
• The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices fornode-negative breast cancer
  European Journal of Surgical Oncology, 1999
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
  Histopathology, 1991